Pair Name	Shikonin, BEZ235
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Expression	CD44	hsa960
	Up-regulation	Phosphorylation	MAPK8	hsa5599
	Down-regulation	Expression	NANOG	hsa79923
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	POU5F1	hsa5460
	Down-regulation	Expression	PROM1	hsa8842
	Down-regulation	Phosphorylation	RPS6KB1	hsa6198
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
Result	We found that low doses shikonin and dual PI3K-mTOR inhibitor (BEZ235) have a synergistic effect that inhibits the spheroid formation from chemoresistant lung cancer sublines. Inhibiting the proliferation of lung cancer stem cells is believed to reduce the recurrence of lung cancer; therefore, shikonin's anti-drug resistance and anti-cancer stem cell activities make it a highly interesting molecule for future combined lung cancer therapy.